{"id":1527,"date":"2020-01-07T07:00:00","date_gmt":"2020-01-07T07:00:00","guid":{"rendered":"https:\/\/oncopeptides.com\/mfn_news\/oncopeptides-ab-oncopeptides-starker-sin-regulatoriska-enhet-och-utser-karin-eklund-vanderpol-till-head-of-regulatory-affairs\/"},"modified":"2026-02-23T13:18:25","modified_gmt":"2026-02-23T13:18:25","slug":"oncopeptides-ab-oncopeptides-starker-sin-regulatoriska-enhet-och-utser-karin-eklund-vanderpol-till-head-of-regulatory-affairs","status":"publish","type":"mfn_news","link":"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-starker-sin-regulatoriska-enhet-och-utser-karin-eklund-vanderpol-till-head-of-regulatory-affairs\/","title":{"rendered":"Oncopeptides AB: Oncopeptides st\u00e4rker sin regulatoriska enhet och utser Karin Eklund Vanderpol till Head of Regulatory Affairs"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/p>\n<p class=\"mfn-wp-retain\">STOCKHOLM &#8211; 7 januari 2020 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO) tillk&auml;nnager idag att Karin Eklund Vanderpol har utsetts till chef f&ouml;r Oncopeptides regulatoriska funktion. Karin har 20 &aring;rs erfarenhet fr&aring;n olika roller i arbetet med regulatoriska fr&aring;gor, och kommer n&auml;rmast fr&aring;n Swedish Orphan Biovitrum d&auml;r hon var Global Regulatory Director. Karin kommer att ing&aring; i Oncopeptides ledningsgrupp och startar sitt arbete idag. Elisabeth Augustsson som har varit ansvarig f&ouml;r funktionen sedan 2015 kommer att forts&auml;tta i en senior roll i den regulatoriska enheten.<\/p>\n<p><\/strong><\/div>\n<p class=\"mfn-wp-retain\">F&ouml;r ytterligare information kontakta:<br \/>Jakob Lindberg, VD f&ouml;r Oncopeptides<br \/>E-post: jakob.lindberg@oncopeptides.com<br \/>Telefon: +46 (0) 8 615 20 40<\/p>\n<p class=\"mfn-wp-retain\">Rein Piir, chef f&ouml;r Investor Relations vid Oncopeptides<br \/>E-post: rein.piir@oncopeptides.com<br \/>Mobiltelefon: +46 (0) 70 853 72 92<\/p>\n<p class=\"mfn-wp-retain\">Information l&auml;mnades f&ouml;r offentligg&ouml;rande den 7 januari 2020 kl. 08.00.<\/p>\n<p class=\"mfn-wp-retain\">Om Oncopeptides<br \/>Oncopeptides &auml;r ett l&auml;kemedelsf&ouml;retag med inriktning p&aring; utveckling av riktade terapier f&ouml;r sv&aring;rbehandlade hematologiska sjukdomar. Bolaget fokuserar p&aring; utvecklingen av produktkandidaten melflufen, ett peptidl&auml;nkat l&auml;kemedel som snabbt levererar ett cellgift till tum&ouml;rceller. Melflufen utvecklas som en ny behandling av den hematologiska cancersjukdomen multipelt myelom och testas f&ouml;r n&auml;rvarande i flertal kliniska studier inklusive den pivotala fas 2-studien HORIZON och den p&aring;g&aring;ende fas 3-studien OCEAN. Oncopeptides har huvudkontor i Stockholm och &auml;r noterat i Mid Cap-segmentet p&aring; Nasdaq Stockholm med kortnamn ONCO.<\/p>\n<p class=\"mfn-wp-retain\">F&ouml;r mer information bes&ouml;k www.oncopeptides.com.<\/p>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment mfn-file-type-pdf\"><a class=\"mfn-attachment-link\" target=\"_blank\" href=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F3002256%2F1170537.pdf\" rel=\"noopener\"><span class=\"mfn-attachment-icon\"><img decoding=\"async\" src=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F3002256%2F1170537.pdf&type=jpg\"><\/span>PDF<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>STOCKHOLM &#8211; 7 januari 2020 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO) tillk&auml;nnager idag att Karin Eklund Vanderpol har utsetts till chef f&ouml;r Oncopeptides regulatoriska funktion. Karin har 20 &aring;rs erfarenhet fr&aring;n olika roller i arbetet med regulatoriska fr&aring;gor, och kommer n&auml;rmast fr&aring;n Swedish Orphan Biovitrum d&auml;r hon var Global Regulatory Director. Karin kommer att ing&aring; [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","news_categories":[],"mfn-news-tag":[174,171,180],"class_list":["post-1527","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news\/1527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=1527"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=1527"},{"taxonomy":"mfn-news-tag","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn-news-tag?post=1527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}